Abstract
Antibodies intended for clinical use have been isolated from non-human primates (NHP), chimpanzees (Pan troglodytes) and macaques (Macaca fascicularis and Macaca mulatta), essentially with the use of the phage-display technology. All studies presenting such isolations have been reviewed and presented here, following the main steps of this technology, and advantages and disadvantages of NHP species were analyzed. Optimization of the tolerance of chimeric NHP-human antibodies by germline humanization was mentioned, and the recent alleviation of legal constraints was revealed. The methodology combining the use of phage-displayed libraries built from immunised NHP with germline humanization should be chosen more frequently to develop well-tolerated IgGs, directed against infectious or human antigens.
Keywords: Antibodies, chimpanzee, clinical, humanization, macaque, non-human primates, patent, phage.
Current Drug Discovery Technologies
Title:Isolation of Antibodies From Non-Human Primates for Clinical Use
Volume: 11 Issue: 1
Author(s): Arnaud Avril, Jeffrey W. Froude, Jacques Mathieu, Thibaut Pelat and Philippe Thullier
Affiliation:
Keywords: Antibodies, chimpanzee, clinical, humanization, macaque, non-human primates, patent, phage.
Abstract: Antibodies intended for clinical use have been isolated from non-human primates (NHP), chimpanzees (Pan troglodytes) and macaques (Macaca fascicularis and Macaca mulatta), essentially with the use of the phage-display technology. All studies presenting such isolations have been reviewed and presented here, following the main steps of this technology, and advantages and disadvantages of NHP species were analyzed. Optimization of the tolerance of chimeric NHP-human antibodies by germline humanization was mentioned, and the recent alleviation of legal constraints was revealed. The methodology combining the use of phage-displayed libraries built from immunised NHP with germline humanization should be chosen more frequently to develop well-tolerated IgGs, directed against infectious or human antigens.
Export Options
About this article
Cite this article as:
Avril Arnaud, Froude W. Jeffrey, Mathieu Jacques, Pelat Thibaut and Thullier Philippe, Isolation of Antibodies From Non-Human Primates for Clinical Use, Current Drug Discovery Technologies 2014; 11 (1) . https://dx.doi.org/10.2174/15701638113109990030
DOI https://dx.doi.org/10.2174/15701638113109990030 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Strain Typing of Mycoplasma pneumoniae and its Value in Epidemiology
Current Pediatric Reviews Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Novel and Viable Acetylcholinesterase Target Site for Developing Effective and Environmentally Safe Insecticides
Current Drug Targets Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Encapsulation – a Convenient Way to Extend the Persistence of the Effect of Eco-Friendly Mosquito Larvicides
Current Organic Chemistry How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation
Current Drug Metabolism The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Current Drug Targets Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review
CNS & Neurological Disorders - Drug Targets Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy Reverse Vaccinology: An Epitope Based Approach to Design Vaccines
Current Bioinformatics The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Hendra and Nipah Infection: Pathology, Models and Potential Therapies
Infectious Disorders - Drug Targets Plasmid DNA Manufacturing Technology
Recent Patents on Biotechnology Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology